Skip to content

Disc Medicine IRON Debt-to-equity

Debt-to-equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
2.2×-0.6×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
0.1×0.0×
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
0.0×
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
0.0×
Beam Therapeutics logo
Beam TherapeuticsBEAM
0.2×+0.1×
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
0.2×-2.6×

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Current ratio24×-13.6×

Where this comes from

Calculated from Disc Medicine’s reported figures.

Based on the most recent quarter.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's debt-to-equity?
Disc Medicine (IRON) reported debt-to-equity of 0× in Q1 2026.
How has Disc Medicine's debt-to-equity changed year-over-year?
Disc Medicine's debt-to-equity decreased by 2.8% year-over-year, from 0× to 0×.
What is the long-term trend for Disc Medicine's debt-to-equity?
Over 3 years (2022 to 2025), Disc Medicine's debt-to-equity has grown at a 76.1% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.